Welcome to our dedicated page for KEEN VISION ACQUISITION SEC filings (Ticker: KVACU), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on KEEN VISION ACQUISITION's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into KEEN VISION ACQUISITION's regulatory disclosures and financial reporting.
Keen Vision Acquisition Corporation reported that it amended its binding letter of intent with Medera Inc. and its subsidiary Novoheart Group Limited. The amendment moves the target date to sign a new replacement merger agreement from April 10, 2026 to April 30, 2026.
The prior merger agreement dated September 3, 2024 had already been terminated and replaced by this letter of intent. The parties continue to use their best efforts to finalize and execute the replacement merger agreement by the new deadline.
Keen Vision Acquisition Corporation reported that it amended its binding letter of intent with Medera Inc. and its subsidiary Novoheart Group Limited. The amendment moves the target date to sign a new replacement merger agreement from April 10, 2026 to April 30, 2026.
The prior merger agreement dated September 3, 2024 had already been terminated and replaced by this letter of intent. The parties continue to use their best efforts to finalize and execute the replacement merger agreement by the new deadline.
Keen Vision Acquisition Corporation, a British Virgin Islands-based SPAC, filed its annual report detailing its structure, deal activity and finances. The company raised $149,500,000 in its IPO and, with a private placement, initially placed $151,368,750 in a U.S. trust account for public shareholders.
Heavy redemptions withdrew $92,398,989, $18,091,743 and $44,294,336.90, leaving trust investments of $57,003,115 and cash outside the trust of $11,206 as of December 31, 2025. Net income for 2025 was $1,910,263, driven mainly by interest and dividends on trust investments.
The SPAC’s original merger agreement with Medera Inc. was terminated and replaced on February 26, 2026 by a binding letter of intent with Novoheart Group Limited, valuing NVH at $100,000,000 and requiring at least $10,000,000 available cash at closing. Keen Vision has extended its business combination deadline multiple times and, as of the report, has until April 27, 2026 to complete a deal before it must liquidate and return remaining trust funds to public shareholders.
Keen Vision Acquisition Corporation entered into a binding letter of intent with Medera Inc. and its subsidiary Novoheart Group Limited (NVH) to negotiate a replacement merger agreement. The new deal would combine NVH, a pre-clinical human disease modeling and drug discovery business, with Keen Vision, which would remain Nasdaq-listed.
The LOI sets NVH’s enterprise valuation at US$100,000,000 and requires the surviving company to have at least US$10,000,000 of available cash at closing after expenses and NVH-related debt. Cash expenses paid at closing are capped at US$700,000 for Keen Vision and US$1,300,000 for NVH, with liquidity coming from the trust account after redemptions, any PIPE financing, and NVH’s cash.
The parties aim to sign the replacement merger agreement by April 10, 2026, with closing conditions largely mirroring a prior merger agreement that has now been terminated under a mutual release. The deal must close within nine months of the LOI, and any PIPE fundraising must also be completed within nine months of signing.
Keen Vision Acquisition Corporation entered into a binding letter of intent with Medera Inc. and its subsidiary Novoheart Group Limited (NVH) to negotiate a replacement merger agreement. The new deal would combine NVH, a pre-clinical human disease modeling and drug discovery business, with Keen Vision, which would remain Nasdaq-listed.
The LOI sets NVH’s enterprise valuation at US$100,000,000 and requires the surviving company to have at least US$10,000,000 of available cash at closing after expenses and NVH-related debt. Cash expenses paid at closing are capped at US$700,000 for Keen Vision and US$1,300,000 for NVH, with liquidity coming from the trust account after redemptions, any PIPE financing, and NVH’s cash.
The parties aim to sign the replacement merger agreement by April 10, 2026, with closing conditions largely mirroring a prior merger agreement that has now been terminated under a mutual release. The deal must close within nine months of the LOI, and any PIPE fundraising must also be completed within nine months of signing.